Clinical Trial Detail

NCT ID NCT02272855
Title A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Takara Bio Inc.
Indications

melanoma

Therapies

Canerpaturev + Ipilimumab

Age Groups: adult

No variant requirements are available.